Subscribe to RSS
DOI: 10.1055/s-0030-1248290
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Acute Hyperhomocysteinemia Impairs Endothelium Function in Subjects with Type 2 Diabetes Mellitus
Publication History
received 27.12.2009
first decision 26.01.2010
accepted 28.01.2010
Publication Date:
03 March 2010 (online)
Abstract
The objective of the present study was to examine the effect of acute, methionine-induced hyperhomocysteinemia (HHCY) on endothelial function and indices of arterial stiffness in subjects with type 2 diabetes mellitus (T2DM). A total of 30 subjects with T2DM, free of macrovascular disease were examined in a crossover study. L-methionine (M) (0.1 g/kg) and water (W) load were given in random order with an interval of about 1 week in between. Endothelial function was assessed by flow-mediated vasodilation (FMD). Arterial stiffness was assessed by determination of augmentation index (AI). Measurements were performed in the fasting state, 1, 2 and 3 h after the M or the W load. Total plasma homocysteine (HCY) levels did not change after W administration, while M administration resulted in a significant increase in HCY concentrations at 3 h. FMD throughout the experiment expressed as area under the curve (AUC) was significantly lower after the M than after the W load. Consistent with impairment in endothelial function, the AUC of AI was significantly higher after the M than after the W administration. Acute HHCY impairs endothelial function and increases arterial stiffness in patients with T2DM. This effect is probably mediated by a reduction of nitric oxide bioavailability in endothelium.
Key words
homocysteine - type 2 diabetes mellitus - flow-mediated vasodilation - augmentation index - arterial stiffness
References
- 1 Avogaro A, Kreutzenberg SV, Fadini G. Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes research and clinical practice. 2008;
- 2 B-Vitamin Treatment Trialists' Collaboration. . Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. American heart journal. 2006; 151 282-287
- 3 Bloomgarden ZT. American Diabetes Association annual meeting, 1999: dyslipidemia, endothelial dysfunction, and glycosylation. Diabetes care. 2000; 23 690-698
- 4 Boger RH, Lentz SR, Bode-Boger SM. et al . Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond). 2001; 100 161-167
- 5 Bots ML, Westerink J, Rabelink TJ. et al . Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. European heart journal. 2005; 26 363-368
- 6 Bowman L, Armitage J, Bulbulia R. et al . Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. American heart journal. 2007; 154 815-823 823 e811-e816
- 7 Chambers JC, McGregor A, Jean-Marie J. et al . Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999; 99 1156-1160
- 8 Chen P, Poddar R, Tipa EV. et al . Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Advances in enzyme regulation. 1999; 39 93-109
- 9 Corretti MC, Anderson TJ, Benjamin EJ. et al . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology. 2002; 39 257-265
- 10 Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 III27-III32
- 11 de Groot PG, Willems C, Boers GH. et al . Endothelial cell dysfunction in homocystinuria. European journal of clinical investigation. 1983; 13 405-410
- 12 Fowler B. Homocysteine: overview of biochemistry, molecular biology, and role in disease processes. Seminars in vascular medicine. 2005; 5 77-86
- 13 Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Current atherosclerosis reports. 2006; 8 100-106
- 14 Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Current drug metabolism. 2007; 8 17-31
- 15 Hoogeveen EK, Kostense PJ, Jakobs C. et al . Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation. 2000; 101 1506-1511
- 16 Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. The Journal of clinical investigation. 1996; 98 5-7
- 17 Mayer O, Filipovsky J, Dolejsova M. et al . Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. Journal of human hypertension. 2006; 20 267-271
- 18 Nappo F, De Rosa N, Marfella R. et al . Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. Jama. 1999; 281 2113-2118
- 19 Nestel PJ, Chronopoulos A, Cehun M. Arterial stiffness is rapidly induced by raising the plasma homocysteine concentration with methionine. Atherosclerosis. 2003; 171 83-86
- 20 Neves MF, Endemann D, Amiri F. et al . Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. Journal of hypertension. 2004; 22 959-966
- 21 O'Rourke MF, Mancia G. Arterial stiffness. Journal of hypertension. 1999; 17 1-4
- 22 Rasouli ML, Nasir K, Blumenthal RS. et al . Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005; 181 159-165
- 23 Romerio SC, Linder L, Nyfeler J. et al . Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults. Atherosclerosis. 2004; 176 337-344
- 24 Shukla N, Thompson CS, Angelini GD. et al . Homocysteine enhances impairment of endothelium-dependent relaxation and guanosine cyclic monophosphate formation in aortae from diabetic rabbits. Diabetologia. 2002; 45 1325-1331
- 25 Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37 1053-1059
- 26 Stuhlinger MC, Oka RK, Graf EE. et al . Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003; 108 933-938
- 27 Tawakol A, Omland T, Gerhard M. et al . Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997; 95 1119-1121
- 28 Tentolouris N, Christodoulakos G, Lambrinoudaki I. et al . Effect of hormone therapy on the elastic properties of the arteries in healthy postmenopausal women. Journal of endocrinological investigation. 2005; 28 305-311
- 29 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ Clinical research ed. 2002; 325 1202
- 30 Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension. 2004; 44 112-116
- 31 Wilkinson IB, Qasem A, McEniery CM. et al . Nitric oxide regulates local arterial distensibility in vivo. Circulation. 2002; 105 213-217
Correspondence
N. TentolourisMD
33 Lakonias Street
115 27 Athens
Greece
Phone: +30/210/745 6261
Fax: +30/210/746 2640
Email: ntentol@med.uoa.gr